Global leukemia therapeutics market was valued USD18584.23 Million in 2020 and is expected to grow at a CAGR of 7.47% during the forecast period. The global leukemia therapeutics market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Supportive government initiatives and policies for promoting cancer awareness are anticipated to fuel the market growth until 2026.

Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning.


The global leukemia therapeutics market can be segmented based on type, gender, age groups, diagnosis, treatment, drugs, route of administration, company and region. Based on type, the market can be bifurcated into chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and others. The chronic lymphocytic leukemia segment led the market in 2020 with share of 34.52%. This can be accredited to the rising geriatric population and increasing funding for research and the development of new cancer therapies. The male and geriatric population are mostly affected by leukemia. The most common diagnosis method of this type of cancer is biopsy whereas, imaging is expected to grow in the near future owing to the improvement and adoption of technology across the globe. Amongst the drug segment, tyrosine kinase inhibitors dominated the global leukemia therapeutic market owing to their greater efficacy and fewer side effects as compared to the rest. Most of the treatments and drugs are administered via injections via intravenous, subcutaneous, intramuscular and intrathecal modes.

Regionally, the leukemia therapeutics market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market with one-third share during the forecast period. This can be attributed to the presence of a large geriatric population base. Besides, the presence of key players in the region is further expected to propel the market over 2026.

Major players operating in the global leukemia therapeutics market include Novartis AG, AbbVie Inc., Roche Holding AG, Amgen Inc., AstraZeneca PLC, Pfizer Inc., Merck & Company Inc., Eli Lilly and Company Ltd., Bristol-Myers Squibb Company, Gilead Sciences Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Stemline Therapeutics Inc., iCell Gene Therapeutics, Otsuka Holdings Company Ltd. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in September 2020, Gilead Sciences Inc. completed the acquisition of Immunomedics Inc., which was one of the biggest acquisition in 2020.
Years considered for this report:
Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022– 2026
Objective of the Study:

  • To analyze historical growth in market size of global leukemia therapeutics market from 2016 to 2020.
  • . To estimate and forecast the market size of global leukemia therapeutics market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global leukemia therapeutics market based on factor, severity, blood cell, age groups, gender, treatment, diagnosis, route of administration, drugs, company and regional distribution.
  • To identify drivers and challenges for global leukemia therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global leukemia therapeutics market.
  • To identify and analyze the profiles of leading players operating in global leukemia therapeutics market.


TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.
TechSci Research calculated the market size of global leukemia therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:

  • Leukemia drugs manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to leukemia therapeutics
  • Market research and consulting firms


The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, global leukemia therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Leukemia Therapeutics Market, By Type:


o Chronic Lymphocytic Leukemia
o Acute Myeloid Leukemia
o Chronic Myeloid Leukemia
o Acute Lymphocytic Leukemia
o Others

  • Global Leukemia Therapeutics Market, By Gender:


o Male
o Female

  • Global Leukemia Therapeutics Market, By Age Groups:


o 0-15
o 15-30
o 30-50


  • o 50+
  • Global Leukemia Therapeutics Market, By Diagnosis:


o Blood test
o Biopsy
o Physical Exam
o Imaging

  • Global Leukemia Therapeutics Market, By Treatment:


o Chemotherapy
o Stem Cell Transplantation
o Immunotherapy
o Targeted Therapy
o Others

  • Global Leukemia Therapeutics Market, By Drugs:


o Tyrosine Kinase Inhibitors
o Antimetabolites
o Hormones (Corticosteroids)
o Monoclonal Antibodies
o Others

  • Global Leukemia Therapeutics Market, By Route of Administration:


o Oral
o Parenteral

  • Global Leukemia Therapeutics Market, By Region:


o North America
? United States
? Canada
? Mexico
o Europe
? Germany
? France
? United Kingdom
? Italy
? Spain
o Asia-Pacific
? China
? Japan
? India
? South Korea
? Australia
o Middle East & Africa
? South Africa
? Saudi Arabia
? UAE
o South America
? Brazil
? Argentina
? Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global leukemia therapeutics market.
Available Customizations:
The following customization options are available for the report:
Company Information

  • Detailed analysis and profiling of additional market players (up to five).